Carla J Greenbaum

Summary

Affiliation: Benaroya Research Institute
Country: USA

Publications

  1. pmc Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data
    Carla J Greenbaum
    Benaroya Research Institute, Seattle, Washington, USA
    Diabetes 61:2066-73. 2012
  2. pmc Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes
    Carla J Greenbaum
    TrialNet Publications, The Biostatistics Center, Rockville, Maryland, USA
    Diabetes Care 31:1966-71. 2008
  3. ncbi High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes
    C J Greenbaum
    Benaroya Research Institute at Virginia Mason, 1201 9th Ave, Seattle, WA 98101, USA
    Diabetologia 48:68-74. 2005
  4. ncbi The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes
    Carla Greenbaum
    Benaroya Research Institute, Diabetes Clinical Research, Seattle, Washington 98101, USA
    Diabetes Care 27:1202-4. 2004
  5. pmc Preservation of beta-cell function in autoantibody-positive youth with diabetes
    Carla J Greenbaum
    Diabetes Research Program, Benaroya Research Institute, Seattle, Washington, USA
    Diabetes Care 32:1839-44. 2009
  6. pmc Parenteral insulin suppresses T cell proliferation to islet antigens
    Carla J Greenbaum
    Benaroya Research Institute, Seattle, WA, USA
    Pediatr Diabetes 12:150-5. 2011
  7. pmc Metabolic tests to determine risk for type 1 diabetes in clinical trials
    Carla J Greenbaum
    Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA
    Diabetes Metab Res Rev 27:584-9. 2011
  8. ncbi Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
    Vicki Seyfert-Margolis
    Immune Teolerance Network, Bethesda, Maryland, USA
    Diabetes 55:2588-94. 2006
  9. ncbi C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
  10. ncbi Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose
    Carla J Greenbaum
    Benaroya Research Institute at Virginia Mason Research Center, Seattle, Washington 98101, USA
    Diabetes 51:951-7. 2002

Research Grants

Detail Information

Publications48

  1. pmc Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data
    Carla J Greenbaum
    Benaroya Research Institute, Seattle, Washington, USA
    Diabetes 61:2066-73. 2012
    ..The robust data on the C-peptide obtained under clinical trial conditions should be used in planning and interpretation of clinical trials...
  2. pmc Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes
    Carla J Greenbaum
    TrialNet Publications, The Biostatistics Center, Rockville, Maryland, USA
    Diabetes Care 31:1966-71. 2008
    ..The Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sensitivity, reproducibility, and tolerability of these procedures...
  3. ncbi High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes
    C J Greenbaum
    Benaroya Research Institute at Virginia Mason, 1201 9th Ave, Seattle, WA 98101, USA
    Diabetologia 48:68-74. 2005
    ..Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes...
  4. ncbi The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes
    Carla Greenbaum
    Benaroya Research Institute, Diabetes Clinical Research, Seattle, Washington 98101, USA
    Diabetes Care 27:1202-4. 2004
  5. pmc Preservation of beta-cell function in autoantibody-positive youth with diabetes
    Carla J Greenbaum
    Diabetes Research Program, Benaroya Research Institute, Seattle, Washington, USA
    Diabetes Care 32:1839-44. 2009
    ..To determine the extent of beta-cell function in youth with diabetes and GAD65 and/or IA2 autoantibodies...
  6. pmc Parenteral insulin suppresses T cell proliferation to islet antigens
    Carla J Greenbaum
    Benaroya Research Institute, Seattle, WA, USA
    Pediatr Diabetes 12:150-5. 2011
    ..Further study is needed to determine whether a therapy that results in sustained suppression of T cell proliferation could yield a measurable clinical benefit...
  7. pmc Metabolic tests to determine risk for type 1 diabetes in clinical trials
    Carla J Greenbaum
    Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA
    Diabetes Metab Res Rev 27:584-9. 2011
    ..Evaluate the reproducibility and relationship of various metabolic tests conducted as part of the Diabetes Prevention Trial-type 1 diabetes...
  8. ncbi Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
    Vicki Seyfert-Margolis
    Immune Teolerance Network, Bethesda, Maryland, USA
    Diabetes 55:2588-94. 2006
    ..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes...
  9. ncbi C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
    ..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome...
  10. ncbi Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose
    Carla J Greenbaum
    Benaroya Research Institute at Virginia Mason Research Center, Seattle, Washington 98101, USA
    Diabetes 51:951-7. 2002
    ..This pattern of abnormalities may be characteristic of islet dysfunction early in the development of type 1 diabetes...
  11. ncbi Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes
    Lisa K Gilliam
    Department of Medicine, University of Washington, 1959 N E Pacific St, Box 357710, Seattle, 98195, USA
    J Autoimmun 25:244-50. 2005
    ..We examined the relationship between diabetes autoantibodies (DAA), human leukocyte antigen (HLA), and clinical course in subjects grouped by clinical diabetes type...
  12. ncbi Non-invasive imaging of beta cell mass: a quantitative analysis
    Ian R Sweet
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Diabetes Technol Ther 6:652-9. 2004
    ..However, beta cells constitute only about 1% of pancreatic mass and are distributed throughout the pancreas within tiny islets of Langerhans that are each less than the spatial resolution of non-invasive imaging technologies...
  13. ncbi Evaluation of leptin levels in subjects at risk for type 1 diabetes
    Lisa K Gilliam
    Department of Medicine, University of Washington, Seattle, WA 98195 7710, USA
    J Autoimmun 26:133-7. 2006
    ....
  14. pmc Changes in autoreactive T cell avidity during type 1 diabetes development
    Nathan E Standifer
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
    Clin Immunol 132:312-20. 2009
    ..These data implicate the outgrowth of T cells expressing higher affinity TCR in a process of antigen-specific T cell avidity maturation during the pre-clinical stage of T1D...
  15. ncbi Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives
    Nathan E Standifer
    Benaroya Research Institute at Virginia Mason, 1201 Ninth Ave, Room 260, Seattle WA, 98101, USA
    Diabetes 55:3061-7. 2006
    ..These data implicate peptides of ppIAPP, GFAP, and IGRP as CTL epitopes for a heterogenous CD8(+) T-cell response in type 1 subjects and antibody-positive relatives...
  16. ncbi Autoimmunity to islet proteins in children diagnosed with new-onset diabetes
    Barbara M Brooks-Worrell
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    J Clin Endocrinol Metab 89:2222-7. 2004
    ..Moreover, the presence of obesity or acanthosis nigracans does not reliably distinguish children with or without islet cell autoimmunity...
  17. ncbi Insulin resistance in type 1 diabetes
    Carla J Greenbaum
    Diabetes Clinical Research, Benaroya Research Institute at Virginia Mason, Seattle, WA 98108, USA
    Diabetes Metab Res Rev 18:192-200. 2002
    ..Finally, one could speculate that it is possible that subsets of people with mild manifestations of the type 1 autoimmune disease process could benefit from treatments aimed at improving the insulin-resistant state...
  18. ncbi Low HERV-K(C4) copy number is associated with type 1 diabetes
    Mike J Mason
    Systems Immunology, Benaroya Research Institute, Seattle, WA
    Diabetes 63:1789-95. 2014
    ....
  19. pmc Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes
    John M Lachin
    The Biostatistics Center, The George Washington University, Rockville, Maryland, United States of America
    PLoS ONE 6:e26471. 2011
    ..These results provide the information needed to accurately evaluate the sample size for studies of new agents to preserve C-peptide levels in newly diagnosed type 1 diabetes...
  20. ncbi Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
    Jennifer Bollyky
    Diabetes Program, Benaroya Research Institute, Seattle, WA, USA
    Mt Sinai J Med 75:385-97. 2008
    ..In this review, we wish to convey the palpable excitement in the field. It is time to determine if we can safely change the course of T1DM...
  21. doi Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus
    Kevin M Krudys
    Department of Bioengineering, Resource Facility for Population Kinetics, University of Washington, PO Box 355061, Seattle, WA 98195, USA
    Metabolism 57:445-7. 2008
    ..Given the simplicity of the OGTT relative to the traditional methods of measuring SI, the oral glucose minimal model may be appropriate for large population studies and clinical trials...
  22. ncbi Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials
    Carla J Greenbaum
    Diabetes Clinical Research, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
    Clin Immunol 104:97-104. 2002
    ....
  23. pmc Avidity-dependent programming of autoreactive T cells in T1D
    Ivana Durinovic-Bello
    Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America
    PLoS ONE 9:e98074. 2014
    ..We propose that maintenance of an NR4A-guided program in low avidity autoreactive T cells in T1D reflects their prior developmental experience influenced by proinsulin expression, identifying a pathway permissive for autoimmunity. ..
  24. doi IL-2 therapy in type 1 diabetes: "Trials" and tribulations
    S Alice Long
    Translational Immunology, Benaroya Research Institute, Seattle, WA, USA
    Clin Immunol 149:324-31. 2013
    ..In this review, we compare results from IL-2 treatment of patients with immune-mediated diseases, discuss possible mechanisms of IL-2 treatment and suggest future directions for use of IL-2 therapy in T1D. ..
  25. ncbi ICA+ relatives with DQA1*0102/DQB1*0602 have expected 0602 sequence and DR types
    Carla J Greenbaum
    Benaroya Research Institute at Virginia Mason Research Center, Seattle, WA 98101, USA
    J Autoimmun 18:67-70. 2002
    ....
  26. pmc Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database
    David M Tridgell
    Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington, USA
    Diabetes Care 34:988-93. 2011
    ..The prevalence of both antibodies decreases with longer duration of type 1 diabetes. We evaluated the interaction between age of diagnosis (onset) and duration of diabetes on the percentage of GADA- and IA-2A-positive subjects...
  27. ncbi Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria
    C J Greenbaum
    Department of Veterans Affairs, Puget Sound Health Care System and the Department of Medicine, University of Washington, Seattle, USA
    Diabetes 50:470-6. 2001
    ..Despite the importance of beta-cell dysfunction in the pathogenesis of type I diabetes, factors other than impaired FPIR must also contribute to postprandial glucose tolerance in these subjects...
  28. ncbi Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes
    Carla J Greenbaum
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
    Diabetes 52:1059-65. 2003
  29. ncbi Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation
    A Plesner
    Department of Medicine, University of Washington, Seattle Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA, USA
    Scand J Immunol 56:522-9. 2002
    ..Sensitized macrophages may be important to high-risk DQB1*0201/*0302-associated type 1 diabetes...
  30. ncbi Systematic screening of potential beta-cell imaging agents
    Ian R Sweet
    Departments of Medicine, University of Washington, Seattle, WA 98195, USA
    Biochem Biophys Res Commun 314:976-83. 2004
    ..In vivo tests of the biodistribution of glibenclamide and fluorodithizone in rats indicated that the compounds were not specifically associated with pancreas, bearing out the predictions of the in vitro screen...
  31. doi Omental roll-up: a technique for islet engraftment in a large animal model
    Thomas R Hefty
    Division of Renal and Pancreas Transplantation, Virginia Mason Medical Center, Seattle, Washington 98101, USA
    J Surg Res 161:134-8. 2010
    ..This site allows placement of the islets in a three-dimensional (3D) matrix, with growth factors, to temporarily culture the islets in vivo while revascularization progresses...
  32. ncbi Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study
    C J Greenbaum
    Department of Medicine, University of Washington, Seattle, USA
    Diabetes 48:170-5. 1999
    ..In addition, there are a group of ICA+ relatives with low AIRg and/or multiple antibodies who have not progressed to diabetes over the course of the study...
  33. ncbi Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes
    R Juneja
    Department of Medicine, University of Washington, Seattle, WA 98108, USA
    Metabolism 50:1008-13. 2001
    ..We therefore conclude that screening with antibodies, mainly ICA and GAD, but not age, BMI, or clinical presentation should be used to identify type 1(1/2) diabetes...
  34. ncbi Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients
    B M Brooks-Worrell
    Department of Medicine, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 48:983-8. 1999
    ..Some subjects demonstrate PBMC responses similar to those of "classic" type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients...
  35. ncbi Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects
    Junbao Yang
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
    J Immunol 176:2781-9. 2006
    ....
  36. ncbi Male sex increases the risk of autoimmunity but not type 1 diabetes
    Jeffrey P Krischer
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Diabetes Care 27:1985-90. 2004
    ..We examined both the effect of the sex of the individual screened as well as the effect of the sex of the individual's proband on diabetes risk variables tested...
  37. ncbi Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Desmond Schatz
    Department of Pediatrics, University of Florida, Gainesville, 32610, USA
    Pediatr Diabetes 5:72-9. 2004
    ..However, preservation of C-peptide production in the prediabetic period appears to indicate non-progression to clinical disease and may serve as a new surrogate for determining response to preventative efforts...
  38. ncbi Role of insulin resistance in predicting progression to type 1 diabetes
    Ping Xu
    Pediatrics Epidemiology Center, University of South Florida, Tampa, Florida 33612, USA
    Diabetes Care 30:2314-20. 2007
    ..The purpose of this study was to determine whether insulin resistance is a risk factor for the development of type 1 diabetes in autoantibody-positive first-degree relatives of diabetic family members...
  39. ncbi Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes
    Maria J Redondo
    Department of Endocrinology, University Clinic of Navarra, 31008 Pamplona, Spain
    J Clin Endocrinol Metab 91:1705-13. 2006
    ..Human leukocyte antigen (HLA) DQ haplotypes have the strongest genetic association with type 1 diabetes (T1DM) risk...
  40. ncbi GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes
    Helena Reijonen
    Benaroya Research Institute at Virginia Mason, Seattle, Washington 98101, USA
    Diabetes 53:1987-94. 2004
    ..1 and Valpha17-Vbeta4. Presence of these high-avidity TcRs indicates a failure to delete autoreactive T-cells that likely arise from oligoclonal expansion in response to autoantigen exposure during the progression of type 1 diabetes...
  41. ncbi Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects
    Nancy A Danke
    Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101, USA
    J Autoimmun 25:303-11. 2005
    ....
  42. ncbi Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes
    Mary Rieck
    Translational Research Program, Benaroya Research Institute, Virginia Mason, Seattle, WA 98101, USA
    J Immunol 179:4704-10. 2007
    ..By identifying an immunologic phenotype in healthy subjects which correlates with the PTPN22 1858C/T genotype, we can now explore specific hypotheses regarding pathogenesis of diseases associated with the PTPN22 1858T variant...
  43. doi Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for Diabetes in Youth Study
    Michelle J Naughton
    Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, 2000 W First St, Winston Salem, NC 27104, USA
    Arch Pediatr Adolesc Med 162:649-57. 2008
    ..To examine the associations between demographic and diabetes management variables and the health-related quality of life (HRQOL) of youths with type 1 or type 2 diabetes mellitus (DM)...
  44. ncbi Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1
    Jay S Skyler
    University of Miami, PO Box 016960 D 110, Miami, FL 33101 6960, USA
    Diabetes Care 28:1068-76. 2005
    ..This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes...
  45. ncbi Future intervention trials in type 1 diabetes
    Terry Wilkin
    Department of Endocrinology and Metabolism, Peninsula Medical School, Plymouth, UK
    Diabetes Care 27:996-7. 2004

Research Grants2

  1. DQB1*0602 RELATIVES--MECHANISMS FOR DIABETES PROTECTION
    Carla Greenbaum; Fiscal Year: 2000
    ..This proposal includes collaborative agreements between the University of Washington and the Universities of Florida (Gainesville), South Florida (Tampa), and Colorado. ..
  2. DQB1*0602 RELATIVES--MECHANISMS FOR DIABETES PROTECTION
    Carla Greenbaum; Fiscal Year: 2001
    ..This proposal includes collaborative agreements between the University of Washington and the Universities of Florida (Gainesville), South Florida (Tampa), and Colorado. ..